Page last updated: 2024-09-04

torcetrapib and ta-8995

torcetrapib has been researched along with ta-8995 in 3 studies

Compound Research Comparison

Studies (torcetrapib)	Trials (torcetrapib)	Recent Studies (post-2010) (torcetrapib)	Studies (ta-8995)	Trials (ta-8995)	Recent Studies (post-2010) (ta-8995)
273	28	83	8	3	6

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bai, C; Cheng, M; Hao, C; Lin, B; Liu, C; Luo, C; Wang, J; Xie, H; Yuan, H; Zhao, D; Zhao, S; Zheng, J	1
Barkas, F; Elisaf, M; Filippatos, TD; Klouras, E	1
Avorn, J; Franklin, JM; Hey, SP; Kesselheim, AS	1

Reviews

2 review(s) available for torcetrapib and ta-8995

Article	Year
Cholesteryl ester transfer protein inhibitors: challenges and perspectives. Expert review of cardiovascular therapy, 2016, Volume: 14, Issue:8 Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Esters; Humans; Lipids; Lipoprotein(a); Lipoproteins, HDL; Oxazolidinones; Quinolines; Sulfhydryl Compounds	2016
Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors. Circulation. Cardiovascular quality and outcomes, 2017, Volume: 10, Issue:6 Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Biomarkers, Pharmacological; Cholesterol Ester Transfer Proteins; Drug Approval; Drug Discovery; Dyslipidemias; Endpoint Determination; Esters; Humans; Lipids; Oxazolidinones; Predictive Value of Tests; Quinolines; Reproducibility of Results; Sulfhydryl Compounds; Time Factors; Treatment Outcome	2017

Article

Year

Cholesteryl ester transfer protein inhibitors: challenges and perspectives.

Expert review of cardiovascular therapy, 2016, Volume: 14, Issue:8

Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Esters; Humans; Lipids; Lipoprotein(a); Lipoproteins, HDL; Oxazolidinones; Quinolines; Sulfhydryl Compounds

2016

Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors.

Circulation. Cardiovascular quality and outcomes, 2017, Volume: 10, Issue:6

Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Biomarkers, Pharmacological; Cholesterol Ester Transfer Proteins; Drug Approval; Drug Discovery; Dyslipidemias; Endpoint Determination; Esters; Humans; Lipids; Oxazolidinones; Predictive Value of Tests; Quinolines; Reproducibility of Results; Sulfhydryl Compounds; Time Factors; Treatment Outcome

2017

Other Studies

1 other study(ies) available for torcetrapib and ta-8995

Article	Year
Design, synthesis and biological evaluation of N,N-3-phenyl-3-benzylaminopropanamide derivatives as novel cholesteryl ester transfer protein inhibitor. Bioorganic & medicinal chemistry, 2016, Apr-15, Volume: 24, Issue:8 Topics: Administration, Oral; Animals; Benzylamines; Cholesterol Ester Transfer Proteins; Cricetinae; Dose-Response Relationship, Drug; Drug Design; Humans; Male; Molecular Docking Simulation; Molecular Structure; Propane; Structure-Activity Relationship	2016

Article

Year

Design, synthesis and biological evaluation of N,N-3-phenyl-3-benzylaminopropanamide derivatives as novel cholesteryl ester transfer protein inhibitor.

Bioorganic & medicinal chemistry, 2016, Apr-15, Volume: 24, Issue:8

Topics: Administration, Oral; Animals; Benzylamines; Cholesterol Ester Transfer Proteins; Cricetinae; Dose-Response Relationship, Drug; Drug Design; Humans; Male; Molecular Docking Simulation; Molecular Structure; Propane; Structure-Activity Relationship

2016